gastroenteritis | GenomeWeb

gastroenteritis

The BD Max Enteric Panel is the latest in the BD Max suite of assays that aid in the diagnosis of infectious gastroenteritis.

The impact study included time-motion analysis of all steps for the EBP compared to stool culture.

The firm's approach to panels is more focused than the competition, according to a BD executive.

Xpert Norovirus is a qualitative in vitro diagnostic test for the identification and differentiation of norovirus genogroup I and genogroup II.

The company makes tests with rapid time-to-results intended for high-volume hospital and pathology labs using its proprietary diagnostic technology, 3Base.

NEW YORK (GenomeWeb) – Luminex said after the close of the market on Monday that the US Food and Drug Administration has cleared three additional targets for its xTAG Gastrointestinal Pathogen Panel.

NEW YORK (GenomeWeb) — Finnish molecular diagnostics firm Mobidiag said today that its Amplidiag Bacterial GE assay has received CE IVD marking and is now commercially available in Europe.

NEW YORK (GenomeWeb) – Becton Dickinson today said that the US Food and Drug Administration has cleared for marketing the firm's BD Max Enteric Bacterial Panel for detecting the common causes of bacterial gastroenteritis.

BioFire Diagnostics has been awarded $1.4 million from the National Institutes of Health for the first year of a planned three-year project to clinically validate the company's FilmArray gastrointestinal panel and help shepherd it through the US Food and Drug Administration appro

NEW YORK (GenomeWeb News) – French theranostics and IVD firm Theradiag will distribute Luminex's xTAG RVP and xTAG GPP assays in France, the companies said recently.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.